



DEMERGER & CAPITAL RAISING

INVESTOR PRESENTATION

NOVEMBER 2023

DISCLAIMER

Disclaimer

This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) ("LGP") and its activities current as at the date of this presentation. The information in this presentation is of general background and does not purport to be complete or to contain all the information which a prospective investor may require in evaluating a possible investment in LGP or that would be required in a prospectus or a product disclosure statement prepared in accordance with the Corporations Act 2001 (Cth) ("Corporations Act").

It should be read in conjunction with LGP's other periodic and continuous disclosure announcements filed with the Australian Securities Exchange, which are available at www.asx.com.au.

This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire LGP's shares or other securities. This document does not constitute or contain an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in LGP.

No liability

The information contained in this document has been prepared in good faith by LGP, however no guarantee representation or warranty expressed or implied is or will be made by any person (including LGP and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document.

To the maximum extent permitted by law, LGP and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice.

Not financial product advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists purely of factual information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product.

An investment in LGP is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

Forward looking statements

Certain information in this document refers to the intentions of LGP, but these are not intended to be forecasts, forward looking statements or statements about the future matters for the purposes of the Corporations Act or any other applicable law. The occurrence of the events in the future are subject to risk, uncertainties and other actions that may cause LGP's actual results, performance or achievements to differ from those referred to in this document. Accordingly, LGP and its affiliates and their directors, officers, employees and agents do not give any assurance or guarantee that the occurrence of these events referred to in the document will actually occur as contemplated. Past performance is no guarantee of future performance.

This presentation may contain forward-looking statements including statements regarding our intent, belief or current expectations with respect to LGP's business and operations, market conditions, results of operations and financial condition, specific provisions and risk management practices. When used in this presentation, the words 'likely', 'estimate', 'project', 'intend', 'forecast', 'anticipate', 'believe', 'expect', 'may', 'aim', 'should', 'potential' and similar expressions, as they relate to LGP and its management, are intended to identify forward-looking statements. Forward looking statements involve known and unknown risks, uncertainties and assumptions and other important factors that could cause the actual results, performances or achievements of LGP to be materially different from future results, performances or achievements expressed or implied by such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof.

Acceptance

By accepting, accessing or reviewing this document you acknowledge and agree to the "Disclaimer" as detailed above.



reset

MIND SCIENCES

OVERVIEW

Key historical figures of the western world

Dr Albert Hofman



- Synthesized LSD in labs of Novartis predecessor
- Self-administered first “trip” in 1943
- Isolated psilocybin

Timothy Leary

- Psychologist, former Harvard psychedelics researcher
- “Turn on, tune in, drop out”
- “The most dangerous man in America” *Richard Nixon*

President Richard Nixon

- War on drugs
- Comprehensive Drug Abuse Prevention and Control Act of 1970



KEY HISTORICAL FIGURES OF THE WESTERN WORLD

*“The Nixon campaign in 1968, and the Nixon White House after that, had two enemies: the antiwar left and black people. You understand what I’m saying? We knew we couldn’t make it illegal to be either against the war or black, but by getting the public to associate the hippies with marijuana and blacks with heroin, and then criminalizing both heavily, we could disrupt those communities. We could arrest their leaders, raid their homes, break up their meetings, and vilify them night after night on the evening news. **Did we know we were lying about the drugs? Of course we did.**”*


John Ehrlichman

Nixon domestic policy advisor




THE PSYCHEDELIC RENAISSANCE

Prohibition as part of the “War on Drugs”




THE PSYCHEDELIC RENAISSANCE

Active/Lethal Dose Ratio and Dependence Potential of Psychoactive Drugs



THE PSYCHEDELIC RENAISSANCE

Notable active research institutions and NFPs globally:



THE CENTRE FOR
PSYCHEDELIC RESEARCH

Imperial College London



UC Berkeley

Berkeley Center for the Science of Psychedelics



MARKET OVERVIEW

AUSTRALIA'S MENTAL HEALTH CRISIS

Mental health is the most common chronic condition in Australia - ABS figures 2017/18

- 4.8m (20.1%) Australians had a mental or behavioural condition
- 3.2m (13.1%) Australians had an anxiety related condition
- Covid pandemic intensified these issues: ~25% of Australians reporting mild-moderate symptoms of depression or anxiety during 1st month of stage 2 restrictions – Medical Journal of Australia
- 4.7m prescriptions for antidepressants issued in Australia during FY2020

Research is growing globally and in Australia into the use of psychedelic drugs including psilocybin to treat mental health conditions such as depression, anxiety and post traumatic stress disorder (PTSD).

PSILOCYBIN & TREATMENT-RESISTANT DEPRESSION

- The mental health crisis is exacerbated by a series of treatment-resistant conditions
- In 2018, a “breakthrough designation” was issued by the US FDA for the treatment of treatment-resistant depression using psilocybin
- Breakthrough designation granted following preliminary clinical evidence suggesting the treatment had potential to be demonstrably better than current treatments
- Interest has intensified following the designation with psychedelics research conducted at some of the world’s premier medical research institutions



MARKET OVERVIEW

TGA RULING

- Reset is uniquely positioned to capitalise on the TGA ruling in early 2023 to reclassify psilocybin and MDMA allowing their prescription by authorised psychiatrists under strictly defined parameters from 1 July 2023
- Australia is the first country to allow psychiatrists to prescribe certain psychedelic substances to patients



Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists

Published: 3 February 2023

From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.

The Therapeutic Goods Administration (TGA) will permit the prescribing of MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression. These are the only conditions where there is currently sufficient evidence for potential benefits in certain patients.



Australian approval of MDMA and psilocybin a 'baby step in the right direction', medical experts say



Australia becomes first country to recognise psychedelics as medicines

OTHER KEY PARTICIPANTS



Clinical drug development and healthcare delivery company focused on MDMA



Clinical drug development and healthcare delivery company focused on MDMA



Joint venture with Canadian company PharmAla Biotech for the supply of synthetic psilocybin and MDMA



MIND MEDICINE
A U S T R A L I A

Not-for-profit focused on education and advocacy of psychedelic medicines with own psychedelic assisted therapy training course for therapists



PSYCHAE
— INSTITUTE —

\$40m non-profit psychedelic research institute dedicated to developing novel psychedelic therapies as registered medical treatments



Psychedelic Research in Science and Medicine

RESET OVERVIEW

INTRODUCING RESET

- Reset incorporated as a 100% subsidiary of Little Green Pharma (LGP) in May 2021
- Leverages LGP's Schedule 9 licensing and long-standing expertise in producing botanical GMP medicines
- Assembled a highly credentialed team of experts across all the required disciplines
- Ideally placed with over two years of background work prior to the TGA down-scheduling decision in 2023

Reset has been at the forefront of the development of the psychedelics industry in Australia. Our four pillars are:



1. MENTAL HEALTHCARE PROVIDER

One of the first clinics in Australia and only one with insurance company (HIF) partnership




2. CLINICAL TRIAL

To test, refine and develop best practice psilocybin protocols and secure Authorised Prescriber approvals for use in clinic



3. CULTIVATION

Cultivation chamber leveraging LGP's licensing and know-how in botanical drug production



4. MANUFACTURE

Two GMP sites leveraging LGP's GMP expertise and licences to import / supply psilocybin products

RESET OVERVIEW

OUR TEAM



Hon. Cheryl Edwards
Chairperson & Independent
Non-Executive Director

Highly credentialled, experienced company director and Chairperson.

A solicitor by profession and a former Minister in the Court Government of Western Australia, she has extensive experience and knowledge of WA's legal and regulatory framework



Angus Caithness
Executive Director

Executive director of LGP and an experienced corporate finance executive and consultant in Australia and international markets. Previously an Executive Director at EY in London and Australia specialising in initial public offerings of large cap mining companies



Shaun Duffy
Non-Executive Director

Founding CEO of Reset and a former Senior Managing Director of FTI Consulting, Mr Duffy previously provided strategy consultancy and corporate advisory services to Reset Mind Sciences' parent company, LGP



Dr Leon Warne
Chief Operating Officer

Former Head of Research & Innovation at LGP, Dr Warne has significant experience in the health sector across clinical, academic, corporate, and start-up settings. Holds extensive qualifications and expertise in a diverse range of fields including medical sciences, higher education, anaesthesia & pain medicine, pharmaceutical R&D and clinical management

RESET OVERVIEW

CLINICAL ADVISORY BOARD



Dr. Stephen Bright

Clinical Psychologist
Co-Founder/VP PRISM
MDMA/PTSD trial
ECU Senior Lecturer



Renee Harvey

Clinical Psychologist
Imperial College London
therapy team.

RESET'S FOUR PILLARS

1. MENTAL HEALTHCARE PROVIDER

- Long-term lease secured for Reset mental health clinic in prime Perth medical precinct
- Site renovations to complete in November 2023 with HIF contributing \$250,000 towards fit-out
- Reset has secured pharmaceutical psilocybin to supply clinical patients under TGA Authorised Prescriber scheme
- Reset progressing Authorised Prescriber scheme approvals for prescribing psychiatrists
- First clinic patients anticipated in Q1 CY2024



RESET'S FOUR PILLARS

HIF ALLIANCE

Reset has entered a strategic alliance with private health insurer Health Insurance Fund of Australia Pty Ltd (HIF) to develop:

- Proof-of-concept health clinic with HIF funding \$250,000 in fit-out costs
- Health economics study
- future specialist clinics under exclusive arrangements



The West Australian

Health | Markets

Little Green Pharma subsidiary teams up with HIF for landmark mental health treatment facility



Reset Mind Sciences, HIF unite for mental health

2. WA'S FIRST PSILOCYBIN TRIAL

- Clinical trial using psilocybin assisted psychotherapy for treatment resistant depression, with one of Australia's most respected psychiatrists Prof. Sean Hood as Principal Investigator, and Reset Advisory Board member Dr. Stephen Bright leading the clinical therapy team
- Trial commencing Q4 CY2023
- Builds on clinical therapy protocols used in successful international clinical trials, with plan to investigate novel aspects of the psychotherapy protocols and adopt protocols for the Reset mental health clinic
- Appointment of clinical therapy team member from highly regarded psilocybin trials conducted by Imperial College, London
- Eligible for R&D rebate set at a rate of 43c per dollar – Australia regarded as one of the best places globally for R&D from a cost perspective



Prof Sean Hood

UWA Associate Dean,
Faculty of Health &
Medical Services

UWA Head of
Psychiatry

SCGH,
Consultant
Psychiatrist



Dr Stephen Bright

Clinical Psychologist
Co-Founder/VP PRISM

Separate MDMA/PTSD trial

ECU Senior Lecturer

Reset Advisory Board
Member




3. CULTIVATION

- Reset leveraging LGP's licensed infrastructure, as well as its experience and expertise in production of botanical drug products
- Purpose-built mushroom cultivation facility co-located at LGP's existing Schedule 9 licensed cannabis cultivation site in Western Australia.
- Cultivation of psilocybin mushrooms commenced in the first half of CY2023 with first batch of psilocybin mushrooms already produced
- Batch is being used for chemical / physical analysis, extraction method testing and inhouse process testing



4. MANUFACTURE

- Reset progressing GMP licence to manufacture psilocybin for human consumption within manufacturing facilities co-located with Reset's mental health clinic
- Separate agreement with LGP granting exclusive access to LGP's GMP manufacturing facilities for psilocybin production if required
- First shipment of psilocybin successfully imported for use in Reset clinical trial and mental health clinic



RESET MIND SCIENCES

AT THE FOREFRONT OF AUSTRALIA'S PSYCHEDELICS INDUSTRY

Mental health clinic
open to patients in
Q1 CY2024

Clinical trial developed over
two years commencing
Q4 CY2023

GMP psilocybin
already imported
for clinical trial and
clinic use

Only company with
insurance fund
partner

Psilocybin mushrooms
already cultivated in
purpose-built Schedule
9 facility

Access to two GMP
manufacturing facilities
and progressing psilocybin
GMP licensing



reset
MIND SCIENCES

DEMERGER &
CAPITAL RAISING

DEMERGER & CAPITAL RAISING

RATIONALE


Reset expected to be demerged from the LGP Group by end of CY2023

- Demerger comprises an in-specie distribution to existing LGP shareholders together with a capital raise of \$2 million on demerger
- Reset to have pre-money valuation of \$2 million on exit, with the funds raised used to:
 - further progress the Reset clinical trial
 - commission the Psychedelic Assisted Psychotherapy (PAP) mental health clinic
 - develop Reset's naturally sourced GMP psilocybin product; and
 - provide working capital

For further information / FAQs, please refer to the LGP investor website and Reset Mind Sciences website:

<https://investlittlegreenpharma.com/site/investor-centre/investor-welcome>

<https://www.resetmind.com.au/>



THE OFFERS

Reset proposes to raise \$2 million (before costs) by the issue of up to 10 million ordinary shares in Reset at \$0.20 per share

- Offers to consist of:
 - I. Priority offer to Eligible LGP Shareholders of up to 5 million shares at \$0.20 per Share to raise up to \$1 million (before costs)
 - II. Public offer of up to 2.5 million Shares to raise up to \$500,000 (before costs) to the general public in Australia and select investors in the United Kingdom and Switzerland, with the ability to accept oversubscriptions of up to \$1 million (before costs); and
 - III. Chair's List offer of up to 2,500,000 Shares to raise up to \$500,000 (before costs) to select investors in Australia, the United Kingdom and Switzerland who have received an invitation from the Chairperson or the Company
- Offers opened on 17 November 2023 and closes on 1 December 2023
- Offers are partially underwritten by LGP¹
- Refer to Appendices for overview of Priority & Public offers

HOW TO APPLY

Priority Offer

- To apply, you will need to complete and submit a Priority Offer Application Form
- To access and complete the form, enter your postcode and unique Priority Offer access code:

<https://apply.automic.com.au/ResetMindSciencesPriority>

Public Offer

To apply, you should follow the instructions on the Public Offer Application Form:

<https://apply.automic.com.au/ResetMindSciences>

Completed applications and payments must be received by the Registry (Automic Group) by the Closing Date of 1 December 2023

Further information and FAQs in relation to the online application process can be found at:

www.resetmind.com.au or

<https://investlittlegreenpharma.com/>

INDICATIVE TIMETABLE & KEY OFFER DETAILS

Lodgement of Prospectus with ASIC	9 November 2023
Priority Offer Record Date	9 November 2023
Opening Date for the Offers	17 November 2023
Closing Date for the Offers	1 December 2023
General meeting of LGP Shareholders to approve the In-specie Distribution	11 December 2023
Completion of transfer of Spin-Out Assets	12 December 2023
Effective date of In-Specie Distribution	12 December 2023
Last day for LGP Shares trading cum In-specie Distribution	13 December 2023
In-specie Record Date	15 December 2023
In-specie Distribution of Reset Shares to LGP Shareholders Despatch of share certificates for Reset Shares distributed under the In-specie Distribution	22 December 2023
Issue of Shares under the Offers Despatch of share certificates for Shares issued under the Offers	22 December 2023

Shares on issue at Prospectus Date	100
Shares to be distributed under the In-specie Distribution	10,000,000
Shares to be issued under the Priority Offer	5,000,000
Shares to be issued under the Chair's List Offer	2,500,000
Shares to be issued under the Public Offer	2,500,000
Total Shares on issue upon completion of the Offers	20,000,100
Options	800,000
Indicative market capitalisation upon completion of the Offers	\$4,000,020



RESET'S INVESTMENT OPPORTUNITY

“We believe Reset Mind Sciences is ideally placed to play a leading role in the evolution of the mental health industry in Australia. Our first mover status has allowed us to attract the highest quality organisations and individuals as potential partners.”

— SHAUN DUFFY



THANKS FOR YOUR TIME

For further information / FAQs, please refer to the LGP investor website and Reset Mind Sciences website:

<https://investlittlegreenpharma.com/site/investor-centre/investor-welcome>

<https://www.resetmind.com.au/>

MORE ABOUT US

Registered & Principal Office

13A Bedbrook Place
Shenton Park WA 6008


Phone: +61 1300 061 504

Email: info@resetmind.com.au

PRIORITY OFFER

- Priority offer to Eligible LGP Shareholders of up to 5 million Shares at an issue price of \$0.20 per Share to raise up to \$1 million (before costs)
- Only LGP Shareholders as at 5:00pm (WST) on 9 November 2023 and located in Australia, or subject to certain restrictions as outlined in the Prospectus¹, United Kingdom and Switzerland are eligible to participate
- If you are an eligible LGP Shareholder under the Priority Offer:
 - you may apply for Reset Shares under the Priority Offer; or
 - If you do not wish to apply for Reset Shares under the Priority Offer, you are not obliged to do anything

1. Refer to restrictions as set out in Sections 1.15 and 1.16 of Prospectus



PUBLIC OFFER

- Offer to the general public in Australia and select investors in the United Kingdom and Switzerland of up to 2 million Shares to raise up to \$500,000 (before costs)
- The Company reserves the right to accept oversubscriptions under the Public Offer of up to \$1 million
- Any Shares not taken up pursuant to the Priority Offer and the Chair's List Offer will be offered under the Public Offer in accordance with the terms set out in the Prospectus

